Gabather AB (publ) (GABA.ST)

SEK 0.4

(-3.61%)

Revenue Summary of Gabather AB (publ)

  • Gabather AB (publ)'s latest annual revenue in 2023 was - SEK , down 0.0% from previous year.
  • Gabather AB (publ)'s latest quarterly revenue in 2024 Q2 was - SEK , down 0.0% from previous quarter.
  • Gabather AB (publ) reported a annual revenue of - SEK in annual revenue 2022, down 0.0% from previous year.
  • Gabather AB (publ) reported a annual revenue of - SEK in annual revenue 2021, down 0.0% from previous year.
  • Gabather AB (publ) reported a quarterly revenue of - SEK for 2024 Q2, down 0.0% from previous quarter.
  • Gabather AB (publ) reported a quarterly revenue of - SEK for 2023 Q3, down 0.0% from previous quarter.

Annual Revenue Chart of Gabather AB (publ) (2023 - 2014)

Historical Annual Revenue of Gabather AB (publ) (2023 - 2014)

Year Revenue Revenue Growth
2023 - SEK 0.0%
2022 - SEK 0.0%
2021 - SEK 0.0%
2020 - SEK 0.0%
2019 - SEK 0.0%
2018 - SEK 0.0%
2017 - SEK 0.0%
2016 - SEK 0.0%
2015 - SEK 0.0%
2014 - SEK 0.0%

Peer Revenue Comparison of Gabather AB (publ)

Name Revenue Revenue Difference
AcuCort AB - SEK NaN%
AlzeCure Pharma AB (publ) - SEK NaN%
BioGaia AB (publ) 1.29 Billion SEK 100.0%
Enzymatica AB (publ) 50.9 Million SEK 100.0%
Enorama Pharma AB (publ) 1.35 Million SEK 100.0%
Klaria Pharma Holding AB (publ.) - SEK NaN%
Moberg Pharma AB (publ) - SEK NaN%
Nanexa AB (publ) 29.32 Million SEK 100.0%
Newbury Pharmaceuticals AB (publ) 36.82 Million SEK 100.0%
ODI Pharma AB 22.44 Million SEK 100.0%
Orexo AB (publ) 638.8 Million SEK 100.0%
Probi AB (publ) 627.68 Million SEK 100.0%
Swedencare AB (publ) 2.32 Billion SEK 100.0%
Swedish Orphan Biovitrum AB (publ) 22.12 Billion SEK 100.0%
Toleranzia AB 50.92 Million SEK 100.0%
Vivesto AB 1.01 Million SEK 100.0%